Boughton Soleil 4

What Happened Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported the sale of 4,651 shares on February 27, 2026. The shares were sold at $15.21 each for total proceeds of $70,742. The filing indicates the sale was executed under a Rule 10b5‑1 trading plan.

Key Details

• Transaction date and price: Feb 27, 2026 — 4,651 shares sold at $15.21 per share.
• Proceeds: $70,742 (gross).
• Trade type: Sale (open‑market sale executed pursuant to a 10b5‑1 plan).
• Footnote: The 10b5‑1 trading plan was adopted by the reporting person on November 18, 2025.
• Shares owned after transaction: Not disclosed in this Form 4.
• Filing timeliness: Form 4 was filed on March 2, 2026; this appears to be timely (filed within the standard SEC deadline).

Context Sales under a 10b5‑1 plan are pre‑arranged and typically follow a schedule set when the plan was adopted; they do not necessarily reflect the insider’s current view of the company. For retail investors, purchases often carry more interpretive weight than routine, preplanned sales. This report is a straightforward disposition of shares by the CLO under an established trading plan.